A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a particular therapy being tested in a clinical trial.